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Abstract
Background: Breast cancer is one of the most common diseases affecting women. Inherited susceptibility genes, 
BRCA1 and BRCA2, are considered in breast, ovarian and other common cancers etiology. BRCA1 and BRCA2 genes have 
been identified that confer a high degree of breast cancer risk.
Objective: Our study was performed to identify germline mutations in some exons of BRCA1 and BRCA2 genes for the 
early detection of presymptomatic breast cancer in females.
Methods: This study was applied on Egyptian healthy females who first degree relatives to those, with or without a 
family history, infected with breast cancer. Sixty breast cancer patients, derived from 60 families, were selected for 
molecular genetic testing of BRCA1 and BRCA2 genes. The study also included 120 healthy first degree female relatives 
of the patients, either sisters and/or daughters, for early detection of presymptomatic breast cancer mutation carriers. 
Genomic DNA was extracted from peripheral blood lymphocytes of all the studied subjects. Universal primers were 
used to amplify four regions of the BRCA1 gene (exons 2,8,13 and 22) and one region (exon 9) of BRCA2 gene using 
specific PCR. The polymerase chain reaction was carried out. Single strand conformation polymorphism assay and 
heteroduplex analysis were used to screen for mutations in the studied exons. In addition, DNA sequencing of the 
normal and mutated exons were performed.
Results: Mutations in both BRCA1 and BRCA2 genes were detected in 86.7% of the families. Current study indicates that 
60% of these families were attributable to BRCA1 mutations, while 26.7% of them were attributable to BRCA2 mutations. 
Results showed that four mutations were detected in the BRCA1 gene, while one mutation was detected in the BRCA2 
gene. Asymptomatic relatives, 80(67%) out of total 120, were mutation carriers.
Conclusions: BRCA1 and BRCA2 genes mutations are responsible for a significant proportion of breast cancer. BRCA 
mutations were found in individuals with and without family history.
Background
Breast cancer is one of the most prevalent diseases affect-
ing women [1]. In Egypt, breast cancer represents 18.9%
of total cancer cases among the Egypt National Cancer
Institute during the year 2001 [2]. Breast cancer is the
most common cause of cancer related deaths among
women worldwide [3]. The etiology of breast cancer
involves environmental factors, inherited genetic suscep-
tibility, genetic changes during progression and interac-
tion among these factors, with the relative importance of
each ranging from strongly genetic or strongly environ-
mental [4]. In the process associated with the develop-
m e n t  o f  b r e a s t  c a n c e r ,  i t  i s  k n o w n  t h a t  m a l i g n a n t
transformation involves genetic and epigenetic changes
that result in uncontrolled cellular proliferation and/or
abnormal programmed cell death or apoptosis. These cel-
lular abnormalities, i.e. cancer cells; arise through accu-
mulation of mutations that are frequently associated with
molecular abnormalities in certain types of genes, such as
proto-oncogenes and tumor-suppressor genes, as a result
of genetic predisposition and/or exposure to physical,
chemical, biological or environmental factors [2]. These
mutations are either inherited (germline) or acquired
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(somatic). Somatic mutation may determine the pheno-
type of a particular breast cancer and may be of clinical
value in determining prognosis. However, only germline
mutations can predetermine an individual's risk of devel-
oping breast cancer.
Two classes of inherited susceptibility genes are consid-
ered in the etiology of breast and other common cancers.
First: Genes have been identified that confer a high
degree of breast cancer risk. These include BRCA1,
BRCA2 and TP53. Because of the great effect these genes
have on cancer risk, one hallmark of these genes is the
creation of a Mendelian autosomal dominant pattern of
cancer. These genes also tend to predispose to earlier
onset, multifocal breast tumors. Second: Variant geno-
types at other loci (polygene) may confer a relatively
smaller degree of cancer risk, but they carried by a larger
proportion of the general population. In the general pop-
ulation, breast cancer usually occurs in the absence of a
strong family history, appears unilaterally, and has a rela-
tively late (often postmenopausal) age at diagnosis [5].
The discovery of breast cancer genes, BRCAl  and
BRCA2, has led to an explosive growth in cancer screen-
ing for population at risk. Every one carries these genes as
part of the normal genetic makeup. Patients who are at
risk for breast cancer carry mutations of these genes.
Early in the last decades, in 1990, genetic studies pro-
vided initial evidence that the risk of breast cancer in
some families is linked to position q2i of chromosome 17
which was characterized by autosomal dominant inheri-
tance. In fact, loss of heterozygosity at 17q was found in
most familial breast and ovarian tumors, suggesting the
involvement of tumor suppressor gene(s) [6,7].
In 1994, the breast cancer susceptibility gene BRCAl,
the most important tumor suppressor gene, was identi-
fied by positional cloning. This gene is expressed in
numerous tissues, including breast and ovary. BRCAl
gene is a large gene spread over approximately 100 kb of
genomic DNA. It is composed of 24 exons, 1 and 4 are
non-coding and are not analyzed, and code for a protein
of 1863 amino acids producing a nuclear protein of about
220 kd. It contains a protein motif, a Ring Finger domain
near the amino acid terminus and a conserved acidic car-
boxyl terminus that functions in transcriptional co-acti-
vation [6,8]. There is evidence that BRCA1 protein being
directly involved in the DNA repair process. The BRCA1
gene product interacts with the RAD51 protein, a key
component in homologous recombination and double
strand break repair [9].
In 1995, the BRCA2 gene was identified at chromosome
13qi2-i3. BRCA2 gene is even larger than BRCA1, consists
of 27 exons, 1 is non-coding and is not analyzed, and
codes for a protein of 3418 amino acids, making a 380 kd
nuclear protein. BRCA2 gene has no obvious homology
to any known gene and the protein contains no well-
defined functional domain [10]. The BRCA2 protein also
interacts with RAD51. Perhaps through this mutual asso-
ciation with RAD51, BRCA1 and BRCA2 associate with
each other at sites of DNA synthesis after the induction of
DNA damage. Nonetheless, BRCA1 and BRCA2 proteins
appear to share a number of functional similarities that
may suggest why mutations in these genes lead to specific
hereditary predisposition to breast and ovarian cancer
[11]. BRCA  genes contribute to DNA repair and tran-
scriptional regulation in response to DNA damage and
cell cycle control. Recent studies suggest that BRCA pro-
teins are required for protecting the genome from dam-
age [12].
Mutations in BRCA genes have been established to pre-
dispose women to breast and ovarian cancer, the end
point of BRCA protein dysfunction. Mutations in both
genes are spread throughout the entire gene. More than
600 different mutations have been identified in BRCAl
gene and 450 mutations in BRCA. The majorities of
mutations, known to be disease-causing, results in a trun-
cated protein due to frame shift, nonsense, or splice site
alternations. Nonsense mutations occur when the nucle-
otide substitution produces a stop codon (TGA, TAA, or
TAG) and translation of the protein is terminated at this
point. Frame shift mutations occur when one or more
nucleotides are either inserted or deleted, resulting in
missing or non-functional protein. Splice site mutations
cause abnormal inclusion or exclusion of DNA in the
coding sequence, resulting in an abnormal protein. Other
kind of mutations results from a single nucleotide substi-
tution is missense mutations in which the substitution
changes a single amino acid but does not affect the
remainder of the protein translation [13,14]. Studies of
BRCAl mutation occurrence suggested that nearly half of
the families at high risk for breast cancer carried BRCAl
mutation [15]. However, other analysis suggest that the
actual incidence of BRCAl in high risk families (>3 cases
of breast and/or ovarian cancer) might be as low as 12.8%
to 16% [4]. Substantial variation in the prevalence of
BRCA1 mutations in high risk families in various coun-
tries has been observed which are more common than
BRCA2 mutations [16,17].
The main objectives of the present work were to iden-
tify germline mutations in BRCA1 (exons 2, 8, 13, 22) and
BRCA2 (exon 9) genes for the early detection of presymp-
tomatic mutation carriers in Egyptian healthy females
who were first degree relatives of affected women from
families with and without family history of breast cancer.
Subjects and Methods
Patients and families
Sixty breast cancer patients (index patients), derived from
60 families, considered being at high risk, due to medici-Ibrahim et al. Journal of Experimental & Clinical Cancer Research 2010, 29:82
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nal examination and they were grid 3 patients, were
selected for molecular genetic testing of BRCA1  and
BRCA2 genes. They were referred to the Clinical Oncol-
ogy Unit in Medical Research Institute, Alexandria Uni-
versity, for chemotherapy as part of their curative
treatment after mastectomy. Selected index patients were
preferred to be at early onset age at diagnosis, possessing
a positive family history and bilateral breast cancer. The
study also included one hundred and twenty healthy first
degree female relatives of index patients either sisters
and/or daughters for early detection of mutation carriers.
The decision to undergo genetic testing was taken after
the participants were informed about benefits and impor-
tance of genetic testing. All studied subjects gave written
informed consent. Index patients were asked for detailed
information on family history of breast or any other can-
cer type in their families. Our study protocol was
approved by the Medical Research Institute, University of
Alexandria, Alexandria, Egypt.
DNA isolation and PCR amplification for the different exons
Blood samples (3 ml each) were collected from the
patients (60 women) and the healthy asymptomatic first
degree female relatives (120 relatives) in EDTA tubes.
Genomic DNA was extracted from peripheral blood lym-
phocytes using a Promega DNA purification kit (Pro-
mega, Madison, USA), following the manufacturer's
instructions. Universal primers (Table 1) were used to
amplify four regions of the BRCA1 gene (exons 2, 8, 13
and 22) and one region of BRCA2 gene (exon 9). The
polymerase chain reaction (PCR) was carried out using
50 ng of DNA, 10 × PCR buffer with 1.5 mM MgCl2, 2 ul
of mixture of 4 mM dNTPs, 20 pmol of each primer and
1U of Tag DNA polymerase at final volume of 25 ul. The
PCR conditions were 96°C for 5 minutes, then 35 cycles
each consists of 30 sec at 94°C, one min at the annealing
temperature of the primer used (mostly around 56-59°C)
and one min at 72°C, followed by one cycle at 72°C for 10
minutes.
Mutation detection using the Single strand conformation 
polymorphism assay (SSCP)
SSCP analysis were used to screen for mutations in the
exons 2, 8, 13, 22 of BRCA1 gene and exon 9 of BRCA2
gene in all studied subjects[18,19]. Every PCR product
was mixed 1:1 with loading buffer (95% formamide, 0.05%
bromophenol blue and 0.05% xylene cyanol), and dena-
ture at 98°C for 10 min and suddenly place in ice. Electro-
phoresis of the denatured PCR products were carried out
in 8% polyacrylamide gel containing 5% glycerol and the
run was performed at 30 mA constant current for 6
hours. After that, the gel was stained by Ethidium Bro-
mide for minutes, washed by water and visualized using
the gel documentation system.
Mutation detection using heteroduplex analysis
Heteroduplex assay was carried out, as a confirmatory
analysis for detecting mutations, in case of families which
had no detected mutation in either of the studied exons of
both genes by SSCP assay. PCR for the patients and nor-
mal samples were carried out using the specific primer of
any one of the studied exons. Equal volumes of PCR
products (form the patient and normal ones) were equally
mixed with loading buffer, the mixture was heated to
denature at 95°C/10 min and cooled to room temperature
over a period of 2 hours to induce heteroduplex forma-
tion. Electrophoresis was done to the mixture through
12% polyacrylamide gel for 6 hours at a constant 60 V.
The gel was stained with Ethidium Bromide for 30 sec-
onds and visualized on the gel documentation system.
Any heteroduplex migrate more slowly through the gel as
compared to its homoduplex counter parts. Sequence
c h a n g e  c o u l d  b e  d e t e c t e d  b y  a n  e x t r a  b a n d  a b o v e  t h e
main homoduplex band.
DNA sequencing of normal and mutated exons
PCR samples showing variant bands as well as that of
normal subjects were analyzed by direct DNA sequenc-
ing technique.
Statistical analysis
The data, either clinical or genetic findings, were statisti-
cally evaluated, interpreted and analyzed using the SPSS
software version 16.
Results
Detected mutations
Mutations were detected in 86.7% of the families (52 from
total 60 families), in either BRCA1 or BRCA2. Of them
60% families were attributable to BRCA1 mutation and
Table 1: Primers' sequences employed in the specific-PCR
Primers Sequence (5'- 3')
BRCA1
Exon 2
Sense: GAAGTTGTCATTTTATAAACCTTT
Antisense: GTCTTTTCTTCCCTAGTATGT
BRCA1
Exon 8
Sense: TGTTAGCTGACTGATGATGGT
Antisense: ATCCAGCAATTATTATTAAATAC
BRCA1
Exon 13
Sense: AATGGAAAGCTTCTCAAAGTA
Antisense: ATGTTGGAGCTAGGTCCTTAC
BRCA1
Exon 22
Sense: ATG TTG GAG CTA GGT CCT TAC
Antisense: GAG AAG ACT TCT GAG GCT ACG
BRCA2
Exon 9
Sense: CAT CAC ACT ACT CAG GAT GAC A
Antisense: GCA TGG TGG TGC ATG CTT GTAIbrahim et al. Journal of Experimental & Clinical Cancer Research 2010, 29:82
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26.7% families were attributable to BRCA2  mutations.
They were identified by using the combination of SSCP
(Figures 1, 2, 3, 4 and 5) and heteroduplex analysis (Fig-
ures 6, 7). Four mutations were detected within the
BRCA1  gene, and one mutation was detected in the
BRCA2 gene. Eighty, from the total 120, asymptomatic
relatives were mutation carriers.
DNA sequencing of normal and mutated exons
R e s u l t s  s h o w e d  t h a t  t h e r e  i s  d i f f e r e n c e  i n  n u c l e o t i d e
sequence between the normal and mutated exons. The
detected BRCA1 mutations comprised four distinct alter-
ations distributed across the coding sequence of the gene.
Two were frame shift mutations localized to exon 2 (185
del AG) and exon 22 (5454 del C) (Table 2), one nonsense
mutation localized to exon 13 (4446 C--T) and one mis-
sense mutation in exon 8 (738 C- -A). The BRCA 2 muta-
tion was frame shift mutation localized to the studied
exon 9 (999 del 5) (Table 3).
Mean age at diagnosis
The mean age at diagnosis of breast cancer in BRCA1
mutation carriers was 42.4 years while in BRCA2 muta-
tion carriers was 34.3 years. The mean age at diagnosis of
breast cancer in BRCA mutation carriers and non carriers
were 39.8 years and 47.1 years respectively.
Family history
Positive family history was found in 39 (65%) families
(included 39 patients their ages at diagnosis ranged from
23 to 45 years). Pathologic mutations were detected in 35
families, in 4 families of them, the affected index cases
and their 1st degree relatives were mutation carriers for
both BRCA1 and BRCA2 gene. Negative family history
patients included a group of 21 women diagnosed with
breast cancer belonging to 21 families (35%). Of them 15
women included in 15 (25%) families their ages at diagno-
sis ranged from 18 to 40 years. Germline mutations in
predisposing BRCA1 gene were detected in these women
and their daughters. In addition, 2 (3.3%) families in
which the index patients had bilateral breast cancer diag-
nosed at ages 44 and 49 years with negative family history
found to have mutation in BRCA1 gene.
Pedigree characteristics
Most index cases, which have a family history of breast
cancer, lack the pedigree characteristics of autosomal
dominant inheritance of cancer predisposition. Example
Figure 1 Single strand conformation polymorphism (SSCP) assay 
for exon 2 (BRCA 1) germline mutations. Lane N, normal female 
control. Lanes 1, 2, 3 and 4 show abnormal pattern of SSCP for patient, 
her sister and her daughters. Lane M, 50 bp DNA ladder.
 
 
 
Figure 2 Single strand conformation polymorphism (SSCP) assay 
for exon 22 (BRCA 1) germline mutations. Lane N, normal female 
control. Lanes 1, 2, 3 and 4 show abnormal pattern of SSCP for patient, 
her sister and her daughters. Lane M, 50 bp DNA ladder.
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of pedigree with positive family history shows the
proband's sister and their mother are affected and one of
her daughters is also affected, the other asymptomatic
daughter of the proband is mutation carrier by DNA test-
ing. This mutation carrier female has two daughters on
testing one is mutation negative and the other is mutation
carrier. Example of pedigree with no family history shows
that the patient (proband) aged 32 years at onset of breast
cancer have 3 daughters and three normal sisters. One of
the asymptomatic daughters on testing found to be muta-
tion carrier for BRCAl  gene. In addition, the grand
daughter of this proband is also mutation carrier.
Discussion
Efforts are underway to reduce the high incidence and
mortality associated with breast cancer, which can be
achieved by the early detection of women at high risk.
Since genetic predisposition is the strongest risk factor,
molecular testing can be considered as the only way for
early detection of breast cancer. DNA testing for breast
cancer susceptibility became an option after the identifi-
cation of the BRCA1 and BRCA2 genes. Germline muta-
tions in either of the two predisposing genes, BRCA1 and
BRCA2, account for a significant proportion of hereditary
breast cancer [14]. Women with either BRCA mutation
have a cumulative lifetime risk of invasive breast cancer
of about 55-85% [20]. Generally, it has not been possible
for clinician to determine which individual in a high risk
families are carriers of BRCA mutations. Women, who
may not have these mutations, may have undergone
unnecessary intervention including prophylactic surgery.
So the availability of the BRCA  analysis has beneficial
impact on the care and counseling of women at risk [4].
Analysis of BRCA1 and BRCA2 genes makes it possible to
identify predisposing mutations in affected persons and
determine risks for family members. Once a mutation is
identified in affected person, asymptomatic family mem-
b e r s  c a n  b e  t e s t e d  f o r  t h i s  o n l y  m u t a t i o n ,  s i n c e  f i r s t
degree relatives of patients with breast cancer have
increased risk for early onset of this cancer [21,22].
All the studied Egyptian patients had invasive breast
carcinoma. From them, 39 patients had both positive
family history and early age at onset and a sample com-
posed of 15 (25%) patients had no family history but had
early onset of the disease. The occurrence of BRCA
mutations in this 25% of the studied patients, with early
onset and no family history of breast cancer, suggests that
the age at diagnosis in patients with negative family his-
Figure 3 Single-strand conformation polymorphism assay for 
exon 13 (BRCA 1) germline mutations. Lane N, normal female con-
trol. Lanes 1, 2, 3 and 4 show abnormal pattern of SSCP for patient, her 
sister and her daughters. Lane M, 50 bp DNA ladder.
 
 
 
Figure 4 Single-strand conformation polymorphism assay for 
exon 8 (BRCA 1) germline mutations. Lane N, normal female control. 
Lanes 1, 2, 3 and 4 show abnormal pattern of SSCP for patient, her sister 
and her daughters. Lane M, 50 bp DNA ladder.
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tory is an important indicator for the presence of patho-
logic mutations and lends support to the screening of
BRCA genes in patients with early onset of the disease.
This finding is nearly similar to a study in a group of
Czeck women (12.9%) with early onset non-familial
breast cancer [14]. In contrast to this, only 2% of non-
familial patients had pathologic germline mutations in
BRCA1 and 2 genes in a group of English patients who
were diagnosed with breast cancer at the age of 30 years
or younger [23]. So the absence of correlation between
family history and the genetic risk attributable to BRCA
genes could reflect variation in family structure and influ-
ence of additional modifier genes [24].
Although BRCA1 and BRCA2 genes exhibit profound
allelic heterogeneity, a large number of repeated muta-
tions have reported, some of them represent founder
mutations. The knowledge of founder mutations can
shorten the search for an inherited disease-associated
mutation. So, in geographic areas where breast cancer
population genetics has not yet been widely studied,
founder mutations can provide a starting place for under-
standing of the public health impact of inherited predis-
posing genes [25]. Ethnicity plays a role in hereditary
breast cancer through its association with particular
founder mutations. Founder mutations in populations
with different national groups have been described in
Ashkenazi Jews, Icelanders, French and other popula-
tions [26-29]. With knowledge of these mutations, it may
be better to screen for a small number of founder BRCA
mutations in all early onset cancer cases, rather than to
attempt comprehensive mutation screening for the
minority of cases with a strong family history [30].
The purpose of doing BRCA  testing in the current
study was to find and examine the biodiversity of a muta-
tions in families of patients with breast cancer for the aim
of early detection of presymptomatic relatives who are
carriers for mutation. It is difficult to identify all muta-
tions in these large genes, so we searched for mutations in
certain exons of BRCA 1 and 2 genes. These exons con-
tain frequently recurring mutations described worldwide,
but the type of mutations identified can differ consider-
ably from country to country. Only few mutations are dis-
persed world wide [31]. In the present study we searched
for three founder mutations in exons 2, 22, of BRCA1
gene, and 9, of BRCA2  gene. In addition, two middle
regions (exons 8 and 13) of BRCA1 gene were investi-
gated for the presence of mutation.
Figure 5 Single-strand conformation polymorphism assay for 
exon 9 (BRCA 2) germline mutations. Lane N, normal female control. 
Lanes 1, 2, 3 and 4 show abnormal pattern of SSCP for patient, her sister 
and her daughters. Lane M, 50 bp DNA ladder.
 
   
Figure 6 Shows Heteroduplex analysis for germline mutations. 
Lane M marker, Lane 1 shows normal pattern, Lanes 2-5 BRCA1 abnor-
mal patterns, Lane 2 exon 2 patients, Lane 3 exon 8 patient, Lane 4 
exon 13 patient, Lane 5 exon 22 patient, Lane 6 BRCA2 exon 9 abnor-
mal pattern
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The majorities of mutations, known to be disease-caus-
ing, consist of small frame shift deletions, small insertions
and nonsense or splice site mutations, which all result in
a truncated protein. Because of the lack of known struc-
ture-function relationships, only truncating mutations
are usable for medical management of carrier individuals
[14]. In the current study four truncating mutations and
one missense mutation were detected among the major-
ity of the studied patients and in more than half of their
asymptomatic first degree female relatives. The truncat-
ing mutations were three frame shift mutations and one
nonsense mutation. All mutations were repeated in 6 or
more families. The recurrent mutations were found in all
(100%) families with detected mutations. This finding is
similar to the study of Corski et al. [32], which found
recurrent mutations in 93% of families with detected
mutations.
The first studied founder mutation in the current study
was the frame shift mutation 185 del AG in exon 2 of
BRCA1 gene. It was identified in 10% of families (index
cases and their asymptomatic relatives). This mutation
was detected with high frequency in Ashkenazi Jews [33],
in two Spanish families [34], in 3 of 4 families with Ashke-
nazi Jewish ancestry in France [35] and in non-Ashkenazi
groups across the middle east, Turkey, England, Iran, Asia
and India [33,36].
The second studied founder mutation in BRCA1 gene is
a frame shift mutation in exon 22 (5454 del C). It is
recently detected in 16.7% Filipino patients and their
asymptomatic relatives [28]. The knowledge about this
mutation is limited [29]. The third studied founder muta-
tion in BRCA2 gene is the frame shift (5-base deletion)
mutation in exon 9 (999 del 5). This mutation is recurrent
and proposed as an ancient founder mutation. It has been
identified as a strong founder in Iceland [37,38]. Also it
w a s  i d e n t i f i e d  i n  F i n n i s h  b r e a s t  c a n c e r  f a m i l i e s  [ 3 9 ] ,
which may reflect ancient genetic relationships between
European populations. Other BRCA2 founder mutations
in other exons have been reported in Filipino patients
[28], and in Jewish patients [40]. In the present study,
BRCA2 mutation is frequently repeated among different
families (26.7%) in both patients and their relatives, sug-
gesting a founder effect in our population. The presence
of this mutation is not limited to those patients having a
positive family history of the disease. Some patients car-
rying this mutation have negative family history. Failure
to identify family history may be attributed to small fam-
ily size and young relatives. For BRCA2, a study [39] has
provided evidence that mutation in a ~3.3 kb nucleotide
region of exon 11 (denoted the ovarian cancer cluster
region, OCCR) is associated with a higher incidence of
ovarian cancer relative to breast cancer. So, there is a sug-
gestion that mutation in OCCR is less penetrate for
breast cancer at younger ages. In the current study, the
BRCA2 mutation in exon 9 is outside the OCCR. This
explains why all the Egyptian breast cancer patients hav-
ing this mutation are of young age, less than forty.
In our study, the identified repeated mutation in exon
13 of BRCA1 gene is a nonsense mutation (4446 C--T). It
was detected in 20% of families. This mutation was found
frequently in French-Canadian families and two families
in France [35]. These multiple instances of mutation did
not represent a founder effect many generations in the
past. There was evidence for multiple independent
BRCA1 mutational events and so multiple origins [41].
The 4446 C--T mutation is one of the most common
mutations found in the Breast Cancer Information Core
Data base. These mutations are likely to have arisen inde-
pendently owing to the presence of mutational hot spots
in the coding sequence of the gene [42].
The last investigated exon in BRCA1 gene for detection
of mutation was exon 8. It has been found that 13.3% of
index patients and half their asymptomatic relatives have
mutation in exon 8(738 C--A). This mutation is a mis-
sense mutation predicted to destroy the protein ring-fin-
ger. Hamann et al. [37] found one missense mutation in
exon 8 of BRCA1 gene in Germany.
Figure 7 Shows Heteroduplex analysis for germline mutations in 
both BRCA genes (BRCA1 exons 2, 8, 13, 22 and BRCA2 exon 9; 
double heterozygote), inherited in a family. Lane M marker, Lane N 
normal control, Lane 1 for patient, Lane 2 and 3 for her daughters, in 
every exon.
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The coexistence of more than founder mutation has
been reported in some Ashkenazi Jewish families [40]. In
the current study, four families of the 60 Egyptian families
were found to have inherited mutation in both BRCA1
and BRCA2 genes, they are double heterozygote. Previ-
ous studies described an Ashkenazi Jewish patient found
to have germline mutations in both BRCA1 and BRCA2
genes [43]. The potential explanation for the occurrence
of the two mutations occurring in the same individual is
that  BRCA1  and  BRCA2  have been implicated in the
maintenance of genomic integrity [9,11].
Collectively, it is obvious that BRCA1 and/or BRCA 2
mutations have been found to account for a greater pro-
portion of breast cancer patients among the studied fami-
lies. This observation might be due to the relatively young
ages of diagnosis of breast cancer and that the hereditary
cancers occur disproportionally in young women. The
accumulation of BRCA1 and BRCA2 mutations data from
sets of families revealed the prevalence of different muta-
tions and the significance of the putative recurrent
founder mutations in Egyptians. The high frequency of
any recurrent mutation (frame shift), so far, suggest that
there may be a strong BRCA1 and 2 founder effects in
Egyptian population. The presence of putative founder
mutations, which leading to reduce genetic heterogeneity
of BRCA genes, facilitates carrier detection and genetic
counseling. Therefore, in countries, where founder muta-
tions are present, it is more economical to screen all cases
for founder mutations than do perform a complete screen
for the two genes on a subset of familial cases. Mutations
analysis for a limited set of founder mutations requires
much less time, resources and labor than complete
screening of genes, resulting in a significant reduction in
cost per mutation detected, and a greater number of
mutations will be found.
In the present study, eight index cases and their families
showed negative results (i.e. no detected mutation in
BRCA1 or BRCA2). This can be explained on the basis
that, there may be no inherited predisposition to the dis-
ease. In addition, failure to detect a mutation does not
exclude the possibility that the individual has predispos-
ing BRCA1 or BRCA2 mutation as we did not screen the
whole gene. These families, in whom no BRCA mutations
have been identified in the proband, have no risk of pass-
ing the mutation to their off spring and can be considered
to have breast cancer risk equal to that of the general
population, if there is no evidence for a breast cancer
gene inherited from the other side of the family (paternal
side) [4]. It is appropriate to offer mutation analysis to
both parents of an individual with a BRCA cancer predis-
posing mutation. In our study, four affected index cases
had mutation in BRCA1 gene, their mothers were died
from breast cancer before the beginning of the genetic
testing, and they might be obligate carriers for BRCA1
mutation. For sisters of an index case, the risk depends on
the genetic status of the index case's parents. The risk
that a sister of an index case will inherit the BRCA1 or
BRCA2 mutation is 50%, if their mother has the mutation.
The risk of developing cancer, however, depends upon
variables including the peretrance of the mutation, and
age of the individual. The BRCA genes are highly pere-
trant and the studied females had a young age at onset of
breast cancer. For daughters of an index case identified as
having  BRCA1  or  BRCA2  m u t a t i o n s,  t h ey  h a v e  a  5 0 %
chance of inheriting the mutation.
Counseling was offered to each of the studied family.
Women who not likely to have inherited a BRCA muta-
tion understand that they remain at risk of developing
sporadic breast cancer at a rate roughly equivalent to that
of the general population. Women with putative inherited
BRCA mutations confer an increased risk of developing
Table 2: Sequencing data of exon 22 of BRCA1 gene which amplified from healthy woman (control) and patient with 
breast cancer, the alignment was carried out using Clustal W 1.9 program.
Subject Nucleotide sequence Number
Control TGAAACCTGCCCTAATAATTCAGTCATCTCTCAGGATCTTGATTATAAAGAAGCAAAATG 60
Patient TGAAACCTACCTTTATAACTTAGTCCAATCTCTAGATTTTGATTTTAAAGAAACAAATAG 
******** ** * **** * **** **** *** ****** ******* **** *
60
Control TAATAAGGAAAAACTACAGTTATTTATTACCCCAGAAGCTGATTCTCTGTCATGCCTGCA 120
Patient TAATAAGGAAAAACTACAGTTATTTATTACCCCAGAAGCTGATTCTCTGTCATGCCTGCA 
************************************************************
120
Control GGAAGGACAGTGTGAAAATGATCCAAAAAGCAAAAAAGTTTCAGATATAAAAGAAGAGGT 180
Patient GGAAGGACAGTGTGAAAATGATCCAAAAAGCAAAAAAGTTTCAGATATAAAAGAAGAGGT
 ************************************************************
180Ibrahim et al. Journal of Experimental & Clinical Cancer Research 2010, 29:82
http://www.jeccr.com/content/29/1/82
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breast cancer [44]. For counseling of women identified as
having a double heterozygote for mutations in BRCA1
and BRCA2, the risk of transmitting a breast cancer sus-
ceptibility gene to any daughters is ¾ [45]. Asymptomatic
relatives who test negative for the specific mutation (i.e.
do not carry the mutation found in the index cases) are at
no increased risk by being related to carriers and have no
risk of passing the mutation to their off spring.
Conclusion
BRCA1 and BRCA2 genes mutations are responsible for a
significant proportion of breast cancer. BRCA mutations
were found in individuals with and without family his-
tory.
Recommendations
Treatment of advanced breast cancer is often useless and
disfiguring, making early detection is of high priority in
medical management of the disease. Molecular testing is
the only way for early detection of breast cancer. Muta-
tional analysis for a limited set of founder mutations
requires much less time, resources, and labor than com-
plete sequencing. Recommendations can be made for
public health action on molecular genetic testing. The
increased public awareness of the nature and prevalence
of breast cancer may result in an increased demand for
genetic testing for breast cancer susceptibility. It is valu-
able to offer genetic testing to newly diagnosed cases with
breast cancer for the purpose of clinical management and
as a mean to identify presymptomatic carrier relatives for
prevention.
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